Ryan Widau to Erlotinib Hydrochloride
This is a "connection" page, showing publications Ryan Widau has written about Erlotinib Hydrochloride.
Connection Strength
0.039
-
Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results. Clin Lung Cancer. 2018 05; 19(3):213-220.e4.
Score: 0.039